Login to Your Account

Clinic Roundup

Friday, December 16, 2011
• Human Genome Sciences Inc., of Rockville, Md., and GlaxoSmithKline plc, of London, said they started dosing in BLISS-SC, a new Phase III trial of Benlysta (belimumab) administered subcutaneously once weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription